Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in New Onset Generalized Myasthenia Gravis
NCT02950155Phase 3Completed
- Start
- Oct 2016
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in myasthenia gravis (MG). Started Oct 2016; status: completed.
02
Drugs
rituximab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT02950155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02950155.